



ASH 2024

66th ASH Annual Meeting and Exposition

December 7–10, 2024
San Diego, US



TOP ABSTRACTS

The MPN Hub Steering Committee have provided their recommendations for the top abstracts to look out for in MPN at the ASH 2024 Congress.

ASH 2024: Top abstracts in MPN

December 7–10, 2024

| Saturday, December 7, 2024 | | | |
|-------------------------------------|---|--------------------|---------------------------|
| Abstract | Title | Speaker | Time (PT) |
| 104 View | Clinical Relevance of the Integrative Analysis of Gut Microbiome and Metabolomics in Myeloid Neoplasms: Correlations with Genomic Profiles, Treatment Response/Complications and Clinical Outcome | Alessia Campagna | 09:45 |
| 241 View | Prognostic Value of Response to First-Line Hydroxyurea According to Ipset Stratification in Essential Thrombocythemia | Marta Santaliestra | 14:00 |
| 242 View | Revised ELN Criteria in Polycythemia Vera Identify an Increased Risk Phenotype for Thrombotic Events Beyond Conventional Risk Stratification. a Multicenter Cooperative Study | Francesca Palandri | 14:15 |
| 243 View | TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms | Shivani Handa | 14:30 |
| 244 View | TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance | Ayalew Tefferi | 14:45 |
| 245 View | Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition | Nico Gagelmann | 15:00 |
| 246 View | Prognostic Implications of Pulmonary Hypertension in Myeloproliferative Neoplasms and Predictors of Hematologic Progression | Orly Leiva | 15:15 |
| 406 View | Intraindividual Comparison of Recognition of Symptom Burden in MPN between Patient- and Physician-Reported Assessment and Its Impact on Survival: an Analysis By the German Study Group for MPN (GSG-MPN) | Kirsi Manz | 16:45 |
| 1790 View | Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia | Lucía Pérez-Lamas | 17:30 (poster session) |
| 1792 View | High Resolution Chest Computed Tomography Responses for a Cohort of Erdheima Chester Disease Patients with Pulmonary Involvement | Long Chang | 17:30 (poster session) |

Sunday, December 8, 2024

| Abstract | Title | Speaker | Time (PT) |
|-------------------------------------|--|----------------------|---------------------------|
| 481 View | A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia | Andrew T. Kuykendall | 09:30 |
| 482 View | Efficacy and Safety of Fedratinib in Patients with Myelofibrosis and Low Baseline Platelet Counts in the Phase 3 Randomized FREEDOM2 Trial | Haifa Kathrin Al-Ali | 09:45 |
| 483 View | Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis | John O. Mascarenhas | 10:00 |
| 485 View | Dynamics of Calr variant Allele Frequency with Therapy in Myeloproliferative Neoplasms | Zi Yun Ng | 10:30 |
| 655 View | Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients | Firas El Chaer | 16:30 |
| 656 View | Initial Results from a Phase 1/2 Study Evaluating Divesiran, a Novel Galnac Conjugated siRNA, in Patients with Polycythemia Vera (SANRECO) | Marina Kremyanskaya | 16:45 |
| 659 View | Apex Part 1: Updated Assessment of Bezucastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM) | Daniel J. DeAngelo | 17:30 |
| 660 View | Redefining Prognosis in Patients with KIT D816V Positive Advanced Systemic Mastocytosis on KIT Inhibitors | Johannes Luebke | 17:45 |
| 3187 View | Overall Survival with Momelotinib Vs Best Available Therapy in Patients with Ruxolitinib-Experienced Myelofibrosis: A Matching-Adjusted Indirect Comparison | Francesca Palandri | 18:00 (poster session) |
| 3178 View | Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis | John O. Mascarenhas | 18:00 (poster session) |

Monday, December 9, 2024

| Abstract | Title | Speaker | Time (PT) |
|-------------------------------------|--|---------------------|---------------------------|
| 871 View | Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms and Evaluation in the Relevant Human Tissue Environment | Alexandros Rampotas | 14:45 |
| 872 View | Mutation-Specific Differences in the Relationship between Obesity and Clonal Hematopoiesis, with a Focus on JAK2V617F and MPN Prevention | Benjamin Rolles | 15:00 |
| 997 View | Hematological Improvement and Other Clinical Benefits of Elritercept As Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the Ongoing Phase 2 Restore Trial | Claire Harrison | 16:30 |
| 998 View | Trial Update from IMproveMF, an Ongoing, Open-Label, Dose-Escalation and -Expansion, Phase 1/1B Trial to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Novel Combination of Imetelstat with Ruxolitinib in Patients with Intermediate-1, Intermediate-2, or High-Risk Myelofibrosis (MF) | John O. Mascarenhas | 16:45 |
| 999 View | A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib | Lucia Masarova | 17:00 |
| 1000 View | Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory Myelofibrosis | John O. Mascarenhas | 17:15 |
| 4559 View | Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV) | Aaron T. Gerds | 18:00 (poster session) |

Tuesday, December 10, 2024

| Abstract | Title | Speaker | Time (PT) |
|--------------------------------------|--|-------------|-----------|
| LBA-4 View | Andean Enriched NFKB1 Haplotype Reduces Inflammation and Improves Response to Ropeginterferon Alfa-2b in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) | Jihyun Song | 07:30 |



#ASH24

Follow us on X to keep up to date
with the latest from the congress

@MPN_Hub



Brought to you by

